{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:57:48Z","timestamp":1669921068280},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s40261-018-0670-0","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T09:11:26Z","timestamp":1529917886000},"page":"813-818","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Thrombopoietin Levels During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"38","author":[{"given":"Takashi","family":"Hamada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyoshi","family":"Iriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihito","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,25]]},"reference":[{"issue":"10","key":"670_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327.","journal-title":"N Engl J Med"},{"issue":"24","key":"670_CR2","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251\u20139.","journal-title":"N Engl J Med"},{"issue":"24","key":"670_CR3","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260\u201370.","journal-title":"N Engl J Med"},{"issue":"2","key":"670_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s12185-017-2225-1","volume":"106","author":"KJ Suh","year":"2017","unstructured":"Suh KJ, Lee JY, Shin DY, Koh Y, Bang SM, Yoon SS, et al. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials. Int J Hematol. 2017;106(2):229\u201339.","journal-title":"Int J Hematol"},{"issue":"4","key":"670_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.23923","volume":"90","author":"N Iriyama","year":"2015","unstructured":"Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, et al. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group. Am J Hematol. 2015;90(4):282\u20137.","journal-title":"Am J Hematol"},{"issue":"9","key":"670_CR6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841\u201351.","journal-title":"Lancet Oncol."},{"issue":"5","key":"670_CR7","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123\u20139.","journal-title":"Blood"},{"issue":"20","key":"670_CR8","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"J Clin Oncol"},{"issue":"4","key":"670_CR9","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/10428190801896103","volume":"49","author":"O Hantschel","year":"2008","unstructured":"Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma. 2008;49(4):615\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"670_CR10","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.3892\/or.2016.5110","volume":"36","author":"M Hagihara","year":"2016","unstructured":"Hagihara M, Iriyama N, Yoshida C, Wakita H, Chiba S, Okamoto S, et al. Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: results of a D-First study. Oncol Rep. 2016;36(5):2976\u201382.","journal-title":"Oncol Rep"},{"issue":"8","key":"670_CR11","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23(8):1398\u2013405.","journal-title":"Leukemia"},{"issue":"12","key":"670_CR12","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1124\/dmd.108.022764","volume":"36","author":"K He","year":"2008","unstructured":"He K, Lago MW, Iyer RA, Shyu WC, Humphreys WG, Christopher LJ. Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metab Dispos. 2008;36(12):2564\u201370.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"670_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1046\/j.1365-2141.1996.d01-1966.x","volume":"95","author":"JC Marsh","year":"1996","unstructured":"Marsh JC, Gibson FM, Prue RL, Bowen A, Dunn VT, Hornkohl AC, et al. Serum thrombopoietin levels in patients with aplastic anaemia. Br J Haematol. 1996;95(4):605\u201310.","journal-title":"Br J Haematol"},{"issue":"3","key":"670_CR14","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1046\/j.1365-2141.1997.992915.x","volume":"97","author":"S Kojima","year":"1997","unstructured":"Kojima S, Matsuyama T, Kodera Y, Tahara T, Kato T. Measurement of endogenous plasma thrombopoietin in patients with acquired aplastic anaemia by a sensitive enzyme-linked immunosorbent assay. Br J Haematol. 1997;97(3):538\u201343.","journal-title":"Br J Haematol"},{"key":"670_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.exphem.2017.09.006","volume":"58","author":"X Zhao","year":"2018","unstructured":"Zhao X, Feng X, Wu Z, Winkler T, Desmond R, Olnes M, et al. Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia. Exp Hematol. 2018;58:39\u201343.","journal-title":"Exp Hematol"},{"issue":"1","key":"670_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1600-0609.1997.tb00959.x","volume":"59","author":"F Heits","year":"1997","unstructured":"Heits F, Katschinski DM, Wilmsen U, Wiedemann GJ, Jelkmann W. Serum thrombopoietin and interleukin 6 concentrations in tumour patients and response to chemotherapy-induced thrombocytopenia. Eur J Haematol. 1997;59(1):53\u20138.","journal-title":"Eur J Haematol"},{"issue":"4","key":"670_CR17","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/leu.2012.348","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia. 2013;27(4):914\u201324.","journal-title":"Leukemia"},{"issue":"11","key":"670_CR18","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1002\/cam4.925","volume":"5","author":"N Iriyama","year":"2016","unstructured":"Iriyama N, Hatta Y, Takei M. Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes. Cancer Med. 2016;5(11):3223\u201334.","journal-title":"Cancer Med"},{"issue":"2","key":"670_CR19","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s12185-012-1138-2","volume":"96","author":"J Imagawa","year":"2012","unstructured":"Imagawa J, Tanaka H, Matsumoto K, Morita K, Harada Y, Harada H. A sharp fluctuation in peripheral blood cells shortly after dasatinib administration. Int J Hematol. 2012;96(2):194\u20139.","journal-title":"Int J Hematol"},{"issue":"16","key":"670_CR20","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1182\/blood-2015-01-569129","volume":"126","author":"R Grozovsky","year":"2015","unstructured":"Grozovsky R, Giannini S, Falet H, Hoffmeister KM. Regulating billions of blood platelets: glycans and beyond. Blood. 2015;126(16):1877\u201384.","journal-title":"Blood"},{"issue":"1","key":"670_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1046\/j.1365-2141.1996.4761013.x","volume":"93","author":"P Angchaisuksiri","year":"1996","unstructured":"Angchaisuksiri P, Carlson PL, Dessypris EN. Effects of recombinant human thrombopoietin on megakaryocyte colony formation and megakaryocyte ploidy by human CD34+ cells in a serum-free system. Br J Haematol. 1996;93(1):13\u20137.","journal-title":"Br J Haematol"},{"issue":"2","key":"670_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1046\/j.1365-2141.1996.d01-1813.x","volume":"94","author":"T Ito","year":"1996","unstructured":"Ito T, Ishida Y, Kashiwagi R, Kuriya S. Recombinant human c-Mpl ligand is not a direct stimulator of proplatelet formation in mature human megakaryocytes. Br J Haematol. 1996;94(2):387\u201390.","journal-title":"Br J Haematol"},{"issue":"2","key":"670_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1046\/j.1365-2141.1996.d01-1920.x","volume":"95","author":"ES Choi","year":"1996","unstructured":"Choi ES, Hokom MM, Chen JL, Skrine J, Faust J, Nichol J, Hunt P. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. Br J Haematol. 1996;95(2):227\u201333.","journal-title":"Br J Haematol"},{"issue":"19","key":"670_CR24","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1182\/blood-2010-12-326850","volume":"117","author":"A Mazharian","year":"2011","unstructured":"Mazharian A, Ghevaert C, Zhang L, Massberg S, Watson SP. Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. Blood. 2011;117(19):5198\u2013206.","journal-title":"Blood."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-018-0670-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0670-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0670-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T12:56:39Z","timestamp":1561467399000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-018-0670-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,25]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["670"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0670-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,25]]},"assertion":[{"value":"25 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received to conduct this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"NI. and Y.H. received honoraria and speaker fees from Bristol-Myers Squibb and Novartis Pharma K.K. M.T. reports scholarship funds and speaker fees from Bristol-Myers Squibb and is part of an international clinical trial evaluating an investigational drug that was developed by Bristol-Myers Squibb for the treatment of Sj\u00f6gren\u2019s syndrome. The remaining co-authors declare no competing financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}